Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells

Blood

Volumn 121, Issue 5, 2013, Pages 830-839

  Macari, Elizabeth R ^a,b,c   Schaeffer, Emily K ^a,b,c   West, Rachel J ^a,b,c   Lowrey, Christopher H ^a,b,c,d  

^a Department of Medicine ^*  (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NORRIS COTTON CANCER CENTER   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN GAMMA CHAIN; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 1; KRUPPEL LIKE FACTOR 2; MESSENGER RNA; SIMVASTATIN; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ARTICLE; BCL11A GENE; CELL DIFFERENTIATION; ERYTHROID CELL; GENE; GENE EXPRESSION; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATOR GENE;

EID: 84873528384     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-443986     Document Type: Article

References (41)

1. Conley CL, Weatherall DJ, Richardson SN, Shepard MK, Charache S. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood. 1963;21:261-281.
2. Edington GM, Lehmann H. Expression of the sickle-cell gene in Africa. Br Med J. 1955;1(4925): 1308-1311.
3. Lowrey CH, Nienhuis AW. Brief report: treatment with azacitidine of patients with end-stage betathalassemia. N Engl J Med. 1993;329(12):845-848. (Pubitemid 23267212)
4. Saunthararajah Y, Molokie R, Saraf S, et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol. 2008;141(1):126-129. (Pubitemid 351347540)
5. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89(3):1078-1088. (Pubitemid 27121303)
6. Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490-492. (Pubitemid 24291887)
7. Hampton T. Strides made in red blood cell disorders, but substantial barriers to care remain. JAMA. 2008;299(4):395-396. (Pubitemid 351185966)
8. Aliyu Z. Hydroxyurea utilization in Nigeria, a lesson in public health [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110(11):80.
9. Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood. 2011;117(22):5987-5997.
10. Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. 2005;224(2): 171-184.
11. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. (Pubitemid 40261799)
12. Morikawa S, Takabe W, Mataki C, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb. 2004;11(2):62-72.
13. Laufs U, La Fata V, Plutzky J, JK. L. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135. (Pubitemid 28152885)
14. Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003;14(6):575-585. (Pubitemid 37083174)
15. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112(5):720-726. (Pubitemid 41099052)
16. Dai G, Vaughn S, Zhang Y, et al. Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2. Circ Res. 2007;101(7):723-733. (Pubitemid 47494103)
17. Fledderus JO, Boon RA, Volger OL, et al. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28(7):1339-1346.
18. Basu P, Morris PE, Haar JL, et al. KLF2 is essential for primitive erythropoiesis and regulates the human and murine embryonic beta-like globin genes in vivo. Blood. 2005;106(7):2566-2571. (Pubitemid 41510835)
19. Basu P, Lung TK, Lemsaddek W, et al. EKLF and KLF2 have compensatory roles in embryonic beta-globin gene expression and primitive erythropoiesis. Blood. 2007;110(9):3417-3425. (Pubitemid 350106337)
20. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839-1842.
21. Larionov A, Krause A, Miller W. A standard curve based method for relative real time PCR data processing. BMC Bioinformatics. 2005;6:62.
22. Ou CN, Rognerud CL. Rapid analysis of hemoglobin variants by cation-exchange HPLC. Clin Chem. 1993;39(5):820-824. (Pubitemid 23145672)
23. Anderson KP, Kern CB, Crable SC, Lingrel JB. Isolation of a gene encoding a functional zinc finger protein homologous to erythroid Krüppel-like factor: identification of a new multigene family. Mol Cell Biol. 1995;15(11):5957-5965.
24. Zhang P, Basu P, Redmond LC, et al. A functional screen for Krüppel-like factors that regulate the human gamma-globin gene through the CACCC promoter element. Blood Cells Mol Dis. 2005; 35(2):227-235. (Pubitemid 41268658)
25. Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone MA, García-Cardeña G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem. 2005;280(29): 26714-26719. (Pubitemid 41040703)
26. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A. 1994;91(21):9926-9930. (Pubitemid 24311921)
27. Alhashem YN, Vinjamur DS, Basu M, Klingmüller U, Gaensler KM, Lloyd JA. Transcription factors KLF1 and KLF2 positively regulate embryonic and fetal beta-globin genes through direct promoter binding. J Biol Chem. 2011;286(28):24819-24827.
28. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet. 2010;42(9):801-805.
29. Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and gammato beta-globin gene switching. Nat Genet. 2010; 42(9):742-744.
30. Tallack MR, Perkins AC. KLF1 directly coordinates almost all aspects of terminal erythroid differentiation. IUBMB Life. 2010;62(12):886-890.
31. Keller MA, Addya S, Vadigepalli R, et al. Transcriptional regulatory network analysis of developing human erythroid progenitors reveals patterns of coregulation and potential transcriptional regulators. Physiol Genomics. 2006;28(1):114-128. (Pubitemid 46705406)
32. Drissen R, von Lindern M, Kolbus A, et al. The erythroid phenotype of EKLF-null mice: defects in hemoglobin metabolism and membrane stability. Mol Cell Biol. 2005;25(12):5205-5214. (Pubitemid 40781118)
33. Tallack MR, Perkins AC. Megakaryocyte-erythroid lineage promiscuity in EKLF null mouse blood. Haematologica. 2010;95(1):144-147.
34. Tallack MR, Magor GW, Dartigues B, et al. Novel roles for KLF1 in erythropoiesis revealed by mRNA-seq. Genome Res. 2012;22(12):2385-2398.
35. Nilson DG, Sabatino DE, Bodine DM, Gallagher PG. Major erythrocyte membrane protein genes in EKLF-deficient mice. Exp Hematol. 2006;34(6): 705-712. (Pubitemid 43737096)
36. Christianson A, Howson CP, Modell B. March of Dimes Global Report on Birth Defects. New York, NY: March of Dimes Birth Defects Foundation; 2006.
37. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336.
38. Wu J, Lingrel JB. KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1. Oncogene. 2004;23(49):8088-8096. (Pubitemid 39531849)
39. Pilon AM, Arcasoy MO, Dressman HK, et al. Failure of terminal erythroid differentiation in EKLFdeficient mice is associated with cell cycle perturbation and reduced expression of E2F2. Mol Cell Biol. 2008;28(24):7394-7401.
40. Sankaran VG. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology Am Soc Hematol Educ Program. 2011;2011:459-465.
41. Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011; 153(5):655-663.